Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial"

被引：1
|
作者：
Sullivan, Ivana [1 ]
Planchard, David [1 ]
机构：
[1] Gustave Roussy, Dept Med Oncol, 114 Rue Edouard Vaillant, F-94800 Villejuif, France
来源：
JOURNAL OF THORACIC DISEASE | 2016年 / 8卷 / 10期
关键词：
ADULT PATIENTS PTS; ALK-INHIBITOR; CONFER RESISTANCE; SINGLE-ARM; OPEN-LABEL; CRIZOTINIB; NSCLC; CERITINIB; CHEMOTHERAPY; MUTATIONS;
D O I：
10.21037/jtd.2016.10.57
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：E1287 / E1292
页数：6
相关论文
共 50 条
  • [41] Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1
    Kim, D.
    Mehra, R.
    Tan, D. S. W.
    Felip, E.
    Chow, L. Q. M.
    Camidge, D. R.
    Vansteenkiste, J.
    Sharma, S.
    De Pas, T.
    Riely, G. J.
    Solomon, B. J.
    Wolf, J.
    Thomas, M.
    Schuler, M.
    Liu, G.
    Santoro, A.
    Geraldes, M.
    Boral, A. L.
    Yovine, A.
    Shaw, A. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S33 - S34
  • [42] The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer
    Heo, Ja Yoon
    Park, Changhee
    Keam, Bhumsuk
    Ock, Chan-Young
    Kim, Miso
    Kim, Tae Min
    Kim, Dong-Wan
    Kim, Se Hyun
    Kim, Yu Jung
    Lee, Jong Seok
    Heo, Dae Seog
    THORACIC CANCER, 2019, 10 (11) : 2117 - 2123
  • [43] Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)
    Leal, T.
    Wakelee, H.
    Reckamp, K. L.
    Chiappori, A.
    Oxnard, G. R.
    Waqar, S. N.
    Patel, S. P.
    Blumenschein, G. R.
    Neal, J. W.
    Harrow, K.
    Holzhausen, A.
    Selvaggi, G.
    Zhou, J.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1171 - S1172
  • [44] Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naive anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option
    Ricciuti, Biagio
    Lamberti, Giuseppe
    Roila, Fausto
    Metro, Giulio
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S378 - S382
  • [45] Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer
    Awad, Mark M.
    Mastini, Cristina
    Blasco, Rafael B.
    Mologni, Luca
    Voena, Claudia
    Mussolin, Lara
    Mach, Stacy L.
    Adeni, Anika E.
    Lydon, Christine A.
    Sholl, Lynette M.
    Janne, Pasi A.
    Chiarle, Roberto
    ONCOTARGET, 2017, 8 (54) : 92265 - 92274
  • [46] Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer
    Liu, Jingru
    Ma, Shutao
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (06) : 590 - 613
  • [47] Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
    Cameron, L. B.
    Hitchen, N.
    Chandran, E.
    Morris, T.
    Manser, R.
    Solomon, B. J.
    Jordan, V
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (01):
  • [48] The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
    Golding, Brandon
    Luu, Anita
    Jones, Robert
    Viloria-Petit, Alicia M.
    MOLECULAR CANCER, 2018, 17
  • [49] The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
    Brandon Golding
    Anita Luu
    Robert Jones
    Alicia M. Viloria-Petit
    Molecular Cancer, 17
  • [50] ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network
    Lin, H.
    Pan, X.
    Huang, H.
    Salvatore, G.
    Clarke, S.
    West, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S617 - S617
12345